Core Viewpoint - Clearway Energy, Inc. has announced a $100 million At-The-Market equity offering program to raise capital for general corporate purposes, including debt repayment, working capital, and investments [1][3]. Group 1: Equity Offering Details - The company will offer shares of its Class C common stock through an Equity Distribution Agreement with major financial institutions including Morgan Stanley, BofA Securities, Citigroup, J.P. Morgan, and Wells Fargo Securities [1]. - The shares will be sold at market prices on the New York Stock Exchange, with an aggregate sales price of up to $100 million [1][4]. - The offering is made under a prospectus supplement dated August 6, 2025, linked to the company's shelf registration statement effective since August 8, 2023 [2]. Group 2: Use of Proceeds - The net proceeds from the equity offering will be utilized for general corporate purposes, which may include repayment or refinancing of debt, funding working capital, capital expenditures, and potential acquisitions [3]. - The company may also invest any immediate surplus funds in marketable securities and short-term investments [3]. Group 3: Company Overview - Clearway Energy, Inc. is a significant owner of clean energy generation assets in the U.S., with a portfolio of approximately 12 GW of gross capacity across 27 states [5]. - The portfolio includes around 9.2 GW of wind, solar, and battery energy storage systems, and approximately 2.8 GW of dispatchable combustion-based power generation assets [5]. - The company aims to provide stable and growing dividend income to its investors through its diversified and primarily contracted portfolio [5].

Core Insights - Helix Acquisition Corp. II has retained approximately $120 million in its trust account, net of redemptions, representing over 60% of the cash held in trust [1] - The transaction is expected to raise approximately $382 million in gross proceeds, including $120 million from Helix's trust account and about $261 million from a private placement transaction [2] - Helix and TheRas, Inc. (BridgeBio Oncology Therapeutics) plan to expedite the closing of their business combination, pending the satisfaction or waiver of closing conditions [3] Company Overview - Helix Acquisition Corp. II is a special purpose acquisition company (SPAC) formed to effect a merger or similar business combination, having raised $184 million in its initial public offering on February 9, 2024 [4] - TheRas, Inc. (BridgeBio Oncology Therapeutics) is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics targeting RAS and PI3Kα malignancies, initially formed as a subsidiary of BridgeBio Pharma, Inc. [5] Financial Highlights - The combined company will have access to gross proceeds of approximately $120 million from the trust account and approximately $261 million from PIPE financing at the closing [7] - The transaction reflects the lowest redemption rate for a biotech de-SPAC transaction since 2022 [7]

WATERTOWN, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint will participate in a fireside chat at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on Thursday, August 13, 2025 at 10:00 a.m. ET. A live webcast and subsequent ...

Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the Arbutus Board of Directors following resignation of Anuj Hasija Dr. Harry Janssen joins the Arbutus Scientific Advisory Board Strong financial position with cash, cash equivalents and marketable securities of $98.1M WARMINSTER, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage ...

Core Insights - Lexicon Pharmaceuticals is making significant progress in its R&D strategy, with ongoing partnership discussions for pilavapadin and IND-enabling studies for LX9851 on track for completion in 2025 [3][4][8] - The company reported a substantial increase in total revenues for Q2 2025, reaching $28.9 million, compared to $1.6 million in Q2 2024, primarily driven by licensing revenue from Novo Nordisk [11][21] - Lexicon's net income for Q2 2025 was $3.3 million, a notable improvement from a net loss of $53.4 million in the same period last year [14][21] Partnership and Product Development - Partnership discussions for pilavapadin are ongoing, with full Phase 2 data expected to be presented at an upcoming medical meeting [3][8] - LX9851, a novel oral candidate for obesity, is in preclinical development, with an exclusive licensing agreement with Novo Nordisk that includes an upfront payment of $45 million and potential milestone payments up to $1 billion [8][11] - The SONATA Phase 3 study for sotagliflozin in hypertrophic cardiomyopathy (HCM) is progressing well, with over 100 sites initiated across 20 countries [3][16] Financial Performance - Total revenues for Q2 2025 were $28.9 million, consisting of $27.5 million in licensing revenue and $1.3 million from INPEFA® sales [11][21] - Research and development expenses decreased to $15.7 million in Q2 2025 from $17.6 million in Q2 2024, reflecting optimized resource allocation [12][21] - Selling, general, and administrative expenses significantly decreased to $9.4 million in Q2 2025 from $39.2 million in Q2 2024 due to strategic repositioning [13][21] Cash Position and Investments - As of June 30, 2025, Lexicon had $139 million in cash and investments, down from $238 million at the end of 2024, primarily due to severance payments related to strategic changes [15][21] - The company also reported $29 million in restricted cash as of the same date [15][21] Pipeline and Future Outlook - Lexicon is focused on advancing its pipeline, with sotagliflozin being commercially available in the U.S. for heart failure as INPEFA® [7][19] - The company is also preparing for regulatory filings for sotagliflozin in various international markets, with submissions already made in the UAE and Saudi Arabia [16][19]

Company Overview - Zevra Therapeutics, Inc. is a commercial-stage company focused on developing therapies for rare diseases with limited or no treatment options, aiming to provide life-changing therapeutics to affected individuals [3]. Upcoming Events - Members of Zevra's executive leadership team will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference in Boston, MA, on August 13, 2025, at 1:00 p.m. ET [1]. - Management will also be available for one-on-one meetings with registered conference attendees [2]. Investor Relations - A live webcast of the fireside chat will be accessible via the "Events & Presentations" section on Zevra's Investor Relations website [2].

Core Business Performance - Holley Performance Brands reported a core business net sales growth of 3.9% in the second quarter of 2025 compared to the same period in 2024, marking the second consecutive quarter of growth [9][8] - The company's net sales decreased by 1.7% to $166.7 million from $169.5 million year-over-year [8][19] - New product launches contributed approximately $8 million in revenue during the second quarter [5] Financial Highlights - Net income for the second quarter was $10.9 million, or $0.09 per diluted share, down from $17.1 million, or $0.14 per diluted share, in the prior year [8][20] - Adjusted EBITDA for the quarter was $36.4 million, compared to $38.3 million in the previous year [8] - Free cash flow reached $35.7 million, the highest level in the company's history, compared to $24.4 million last year [8][15] Strategic Initiatives - The company successfully mitigated tariff impacts through strategic sourcing and pricing actions, leading to increased guidance visibility [6][15] - Holley has refined its full-year guidance for 2025, projecting net sales between $580 million and $595 million, reflecting a year-over-year growth of 0.8% to 3.4% [10] - The company achieved approximately 6.5% growth in its B2B channel and over 8.6% growth in direct-to-consumer orders during the second quarter [15] Operational Efficiency - Net cash provided by operating activities was $40.5 million, significantly higher than $25.7 million in the prior year [8][25] - The company reported a gross profit of $69.6 million, a slight decrease from $70.3 million year-over-year, but an increase in gross profit margin was noted [19] - Operating income for the second quarter was $27.5 million, compared to $27.9 million in the previous year [19]

Core Insights - Solo Brands, Inc. reported a significant focus on transforming into a smaller, profit-driven business model, achieving nearly $11 million in cash from operations for Q2 2025 [2][3] - The company faced challenges in the Solo Stove segment due to excessive inventory and a shift away from a promotional sales strategy, while Chubbies showed strong growth with a 13.1% increase in sales [2][5] - The company successfully refinanced its debt, eliminated the going concern disclaimer, and reinstated trading of its Class A common stock under the new ticker symbol SBDS [2][12] Financial Performance - For Q2 2025, net sales decreased to $92.3 million, down 29.9% from $131.6 million in Q2 2024, primarily due to declines in the Solo Stove segment [5][9] - Gross profit for Q2 2025 was $56.6 million, representing 61.3% of net sales, a decrease of 150 basis points compared to the prior year [5][9] - Operating expenses decreased by $14.0 million to $66.4 million, a reduction of 17.4%, mainly due to lower marketing and distribution costs [5][9] Segment Performance - Solo Stove segment net sales fell to $38.3 million, a decline of 45.8%, primarily due to reduced direct-to-consumer sales [5][9] - Chubbies segment net sales increased to $44.5 million, up 13.1%, with segment EBITDA improving to $11.5 million, or 25.8% of net sales [9][25] - Adjusted EBITDA for the company was $10.5 million, or 11.4% of net sales, compared to $15.5 million, or 11.7% of net sales in the prior year [5][9] Balance Sheet and Cash Flow - As of June 30, 2025, cash and cash equivalents were $18.1 million, up from $12.0 million at the end of 2024, while inventory decreased to $84.1 million from $108.6 million [8][27] - The company reported a net loss of $20.8 million for Q2 2025, compared to a net loss of $4.0 million in Q2 2024 [5][9] - Total liabilities included $10.0 million in borrowings under the revolving credit facility and $241.2 million under the term loan as of June 30, 2025 [10][11]

Company Overview - Nexxen International Ltd. is a global advertising technology platform specializing in data and advanced TV [3][4] - The company operates a flexible and unified technology stack that includes a demand-side platform (DSP) and supply-side platform (SSP), centered around the Nexxen Data Platform [3] Recent Announcements - Nexxen announced participation in financial conferences, including a fireside chat at the Canaccord Genuity Annual Growth Conference on August 13 and a virtual fireside chat at the Rosenblatt Annual Technology Summit on August 19 [1][5] - Live webcasts of these events will be available on Nexxen's investor relations website, with replays accessible for approximately one year [1] Global Presence - The company is headquartered in Israel and has offices across the United States, Canada, Europe, and Asia-Pacific [4]

Core Insights - Inspired Entertainment, Inc. reported strong financial results for the quarter ended June 30, 2025, with total revenue of $80.3 million, representing a 7% increase year-over-year, primarily driven by record Interactive revenue growth of 45% [8][10][9] Financial Performance - Total revenue for the quarter was $80.3 million, up from $74.8 million in the prior year, with Interactive revenue increasing to $13.6 million from $9.4 million [10][8] - Adjusted EBITDA reached $28.4 million, a 15% increase from $24.7 million in the previous year, with Interactive Adjusted EBITDA growing by 49% year-over-year [8][10] - The company reported a net loss of $7.8 million, compared to a net income of $1.4 million in the same quarter last year [10][8] Segment Performance - The Interactive segment was a key growth driver, with revenue increasing by 45% year-over-year, supported by strong performance in North America and the UK [2][9] - Gaming segment Adjusted EBITDA increased by 35% year-over-year, driven by the successful rollout of Vantage cabinets with William Hill [3][10] - Virtual Sports segment saw sequential growth in revenue and Adjusted EBITDA, with localized content in Brazil showing early promise [4][10] Strategic Developments - The company secured a five-year partnership with Jenningsbet to supply approximately 570 Vantage terminals, enhancing its market presence [8][13] - A comprehensive debt refinancing was completed, issuing £270 million in senior secured notes and securing a new £17.8 million revolving credit facility [8][9] Operational Highlights - The Interactive segment's Adjusted EBITDA margin expanded to 67%, reflecting the scalability of digital operations [2][10] - The Leisure segment performed steadily, with year-to-date revenue up 5% and Adjusted EBITDA up 19% compared to the same period last year [5][10]